Clinical Heterogeneity of Anti-GM2-Ganglioside-Antibody Syndrome
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Antiganglioside antibodies are known to play a pathogenic role in Guillain-Barré syndrome (GBS). Either an immunoglobulin (Ig)G- or IgM-type anti-GM2 antibody is detected in rare cases in GBS patients. However, the specific pathogenic role of these antibodies in GBS has not been reported previously. This study aimed to define and characterize the clinical spectrum of GBS with anti-GM2 positivity. Methods We reviewed the database of the Dong-A University Neuroimmunology Team, which has collected sera of GBS and its variants from more than 40 general and universitybased hospitals in Korea. Detailed information about the involved patients was often obtained and then corrected by the charge doctor applying additional questionnaires. Results Four patients with acute monophasic peripheral neuropathy or cranial neuropathy with isolated IgM-type anti-GM2-antibody positivity were recruited. In addition, IgG-type anti-GM2 antibody was solely detected in the sera of another four patients. The IgM-positive group comprised heterogeneous syndromes: two cases of acute motor axonal neuropathy, one of acute inflammatory demyelinating polyneuropathy, and one of isolated facial diplegia. In contrast, all of the cases enrolled in the IgG-positive group manifested with dizziness with or without oculomotor palsy due to cranial neuropathy syndrome. Conclusions This study has identified that anti-GM2 antibody can be found in various subtypes of GBS and its variants in rare cases. Compared to the clinical heterogeneity of the IgMpositive group, the IgG-positive group can be characterized by cranial-dominant GBS variants presenting mainly with oculomotor and vestibular dysfunctions.
Abstract
Background and Purpose Antiganglioside antibodies are known to play a pathogenic role in Guillain-Barré syndrome (GBS). Either an immunoglobulin (Ig)G- or IgM-type anti-GM2 antibody is detected in rare cases in GBS patients. However, the specific pathogenic role of these antibodies in GBS has not been reported previously. This study aimed to define and characterize the clinical spectrum of GBS with anti-GM2 positivity. Methods We reviewed the database of the Dong-A University Neuroimmunology Team, which has collected sera of GBS and its variants from more than 40 general and universitybased hospitals in Korea. Detailed information about the involved patients was often obtained and then corrected by the charge doctor applying additional questionnaires. Results Four patients with acute monophasic peripheral neuropathy or cranial neuropathy with isolated IgM-type anti-GM2-antibody positivity were recruited. In addition, IgG-type anti-GM2 antibody was solely detected in the sera of another four patients. The IgM-positive group comprised heterogeneous syndromes: two cases of acute motor axonal neuropathy, one of acute inflammatory demyelinating polyneuropathy, and one of isolated facial diplegia. In contrast, all of the cases enrolled in the IgG-positive group manifested with dizziness with or without oculomotor palsy due to cranial neuropathy syndrome. Conclusions This study has identified that anti-GM2 antibody can be found in various subtypes of GBS and its variants in rare cases. Compared to the clinical heterogeneity of the IgMpositive group, the IgG-positive group can be characterized by cranial-dominant GBS variants presenting mainly with oculomotor and vestibular dysfunctions.
참고문헌 (29)
- Willison HJ, "Guillain-Barre syndrome", Lancet, 388, pp.717~727 (2016)[DOI]
- Yuki N, "Guillain-Barre syndrome", N Engl J Med, 366, pp.2294~2304 (2012)[DOI]
- Bae JS, "Guillain-Barre syndrome in Asia", J Neurol Neurosurg Psychiatry, 85, pp.907~913 (2014)[DOI]
- Wakerley BR, "Guillain-Barre and Miller Fisher syndromes--new diagnostic classification", Nat Rev Neurol, 10, pp.537~544 (2014)[DOI]
- Uncini A, "Electrodiagnostic criteria for Guillain-Barre syndrome: a critical revision and the need for an update", Clin Neurophysiol, 123, pp.1487~1495 (2012)[DOI]
- Kuwabara S, "Axonal Guillain-Barre syndrome: concepts and controversies", Lancet Neurol, 12, pp.1180~1188 (2013)[DOI]
- Kim JK, "When is facial diplegia regarded as a variant of Guillain-Barre syndrome?", J Peripher Nerv Syst, 20, pp.32~36 (2015)[DOI]
- Kim JK, "Acute bulbar palsy as a variant of Guillain-Barre syndrome", Neurology, 86, pp.742~747 (2016)[DOI]
- Wakerley BR, "Polyneuritis cranialis: oculopharyngeal subtype of Guillain-Barre syndrome", J Neurol, 262, pp.2001~2012 (2015)[DOI]
- O'Hanlon GM, "Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies", Autoimmunity, 32, pp.133~144 (2000)[DOI]
- Cavanna B, "Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies", J Neuroimmunol, 114, pp.226~231 (2001)[DOI]
- Rupp A, "Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis", J Peripher Nerv Syst, 18, pp.75~88 (2013)[DOI]
- Khalili-Shirazi A, "Antiganglioside antibodies in Guillain-Barre syndrome after a recent cytomegalovirus infection", J Neurol Neurosurg Psychiatry, 66, pp.376~379 (1999)[DOI]
- Yuki N, "Acute cytomegalovirus infection and IgM anti-GM2 antibody", J Neurol Sci, 154, pp.14~17 (1998)[DOI]
- Asbury AK, "Assessment of current diagnostic criteria for Guillain-Barre syndrome", Ann Neurol, 27(Suppl), pp.S21~S24 (1990)[DOI]
- 김종국, "Prevalence of Anti-Ganglioside Antibodies and Their Clinical Correlates with Guillain-Barré Syndrome in Korea: A Nationwide Multicenter Study", Journal of Clinical Neurology, 10(2), pp.94~100 (2014), 대한신경과학회[DOI]
- Kusunoki S, "Nacetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome", Ann Neurol, 35, pp.570~576 (1994)[DOI]
- Jeong SH, "Nystagmus and ataxia associated with antiganglioside antibodies", J Neuroophthalmol, 31, pp.326~330 (2011)[DOI]
- Chiba A, "Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome", Brain Res, 745, pp.32~36 (1997)[DOI]
- Smyth KA, "Acquired infantile abducens palsy associated with anti-GM2 antibodies", Pediatr Neurol, 44, pp.459~462 (2011)[DOI]
- Susuki K, "A Guillain-Barre syndrome variant with prominent facial diplegia", J Neurol, 256, pp.1899~1905 (2009)[DOI]
- Lopate G, "Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies", Muscle Nerve, 25, pp.828~836 (2002)[DOI]
- Irie S, "Association of anti-GM2 antibodies in Guillain-Barre syndrome with acute cytomegalovirus infection", J Neuroimmunol, 68, pp.19~26 (1996)[DOI]
- Jacob A, "Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders", J Neurol Neurosurg Psychiatry, 84, pp.922~930 (2013)[DOI]
- Jacobs BC, "The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study", Neurology, 51, pp.1110~1115 (1998)[DOI]
- Ang CW, "Cross-reactive antibodies against GM2 and CMVinfected fibroblasts in Guillain-Barre syndrome", Neurology, 54, pp.1453~1458 (2000)[DOI]
- Kuwahara M, "Characterization of the neurological diseases associated with Mycoplasma pneumoniae infection and anti-glycolipid antibodies", J Neurol, 264, pp.467~475 (2017)[DOI]
- Santos Garcia D, "Multiple cranial neuropathy associated with herpes simplex virus infection and anti-GM2 immunoglobulin M antibodies", J Clin Neuromuscul Dis, 10, pp.199~201 (2009)[DOI]
- Visser LH, "Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group", Neurology, 47, pp.668~673 (1996)[DOI]